Filtered By:
Cancer: Lung Cancer

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 49680 results found since Jan 2013.

Reducing the underreporting of lung cancer attributable to occupation: outcomes from a hospital-based systematic search in Northern Italy
Conclusions Through SS, many occupational LCs were found that otherwise would have been lost. Aetiological diagnosis proved to be rich of scientific advantages and practical implications, with attention to equity and social aspects. SS was easy, accountable and fostered multidisciplinary collaboration among medical specialties, significantly reducing underreporting and undercompensation of occupational LC.
Source: International Archives of Occupational and Environmental Health - April 29, 2016 Category: Occupational Health Source Type: research

Low-Dose Lung CT Image Restoration Using Adaptive Prior Features From Full-Dose Training Database
The valuable structure features in full-dose computed tomography (FdCT) scans can be exploited as prior knowledge for low-dose CT (LdCT) imaging. However, lacking the capability to represent local characteristics of interested structures of the LdCT image adaptively may result in poor preservation of details/textures in LdCT image. This paper aims to explore a novel prior knowledge retrieval and representation paradigm, called adaptive prior features assisted restoration algorithm, for the purpose of better restoration of the low-dose lung CT images by capturing local features from FdCT scans adaptively. The innovation lie...
Source: IEE Transactions on Medical Imaging - December 1, 2017 Category: Biomedical Engineering Source Type: research

Zyxin: a mechanotransductor to regulate gene expression.
CONCLUSIONS: Zyxin is a crucial ingredient of the cellular mechanotransducing system and can modulate the gene expression. Given its clinical relevance, zyxin is also a promising target for the diagnosis and treatment of certain diseases. Understanding the role of zyxin in force sensing and gene expression regulating provides a compelling challenge for future biomechanics studies, and offers attractive evidence for zyxin as a potential diagnostic marker and therapeutic target for clinical diseases. PMID: 30657586 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - January 20, 2019 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Targeted therapy in lung cancer —ASCO 2019 update
SummaryNew targeted therapies for patients with non small cell lung cancer were presented at this year ’s ASCO.EGFR exon 20 insertions might soon be treatable with TAK-788, which showed an objective response rate (ORR) of between 25 and 56% with a disease control rate (DCR) between 67 and 100% depending on the presence or absence of brain metastases at baseline. Capmatinib and tepotinib showed durable responses inMET exon 14 mutations as presented in the phase II GEOMETRY trial and the VISION trial. The median duration of response (DOR) was 9.7 months with a median progression free survival (PFS) of 5.42 months in pretre...
Source: Memo - Magazine of European Medical Oncology - November 5, 2019 Category: Cancer & Oncology Source Type: research

Changes in the presenting symptoms of lung cancer from 2000-2017: a serial cross-sectional study of observational records in UK primary care.
CONCLUSION: During 2000-2017, the proportions of lung cancer patients with an index symptom of cough or dyspnoea increased, while the proportion of those with the index symptom haemoptysis decreased. This trend has implications for medical education and symptom awareness campaigns. PMID: 31988087 [PubMed - as supplied by publisher]
Source: The British Journal of General Practice - January 26, 2020 Category: Primary Care Authors: Chowienczyk S, Price S, Hamilton W Tags: Br J Gen Pract Source Type: research

Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab.
Authors: Bukamur H, Katz H, Alsharedi M, Alkrekshi A, Shweihat YR, Munn NJ Abstract The development of checkpoint inhibitors has changed the treatment paradigm for cancer. Checkpoint inhibitors nivolumab, pembrolizumab, and cemiplimab target programmed death-1 (PD-1), whereas durvalumab, avelumab, and atezolizumab target PD-ligand 1. Ipilimumab targets cytotoxic T lymphocyte-associated antigen 4. Used as monotherapy or in combination, these inhibitors have shown remarkable efficacy in melanoma, lung cancer, urothelial cancer, and many other solid tumors, and indications are continuing to evolve. Checkpoint inhibito...
Source: Southern Medical Journal - November 5, 2020 Category: General Medicine Tags: South Med J Source Type: research

ASCO 2020 non-small lung cancer (NSCLC) personal highlights
SummaryIn this article we summarize our personal non-small cell lung cancer (NSCLC) highlights of the virtual ASCO 2020 meeting, covering developments in early and advanced-stage NSCLC. Until recently early stage NSCLC patients were treated independently of their genetic profile. Now the ADAURA study proved that postoperative osimertinib significantly prolongs disease-free survival compared to standard chemotherapy in EGFR-mutated NSCLC , underlining the high efficacy of targeted therapies in early stages. In advanced-stage disease, of course immunotherapy (IO) was at the center of attention. Final analysis of KEYNOTE-189 ...
Source: Memo - Magazine of European Medical Oncology - January 13, 2021 Category: Cancer & Oncology Source Type: research

Dosimetric comparison of coplanar and noncoplanar beam arrangements for radiotherapy of patients with lung cancer: A meta-analysis
CONCLUSION: After combining multicenter results, NCBA plans have significant advantages in reducing V20 of the whole lung and max dose of spinal cord.PMID:33634946 | DOI:10.1002/acm2.13197
Source: Journal of Applied Clinical Medical Physics - February 26, 2021 Category: Physics Authors: Min Ma Wenting Ren Minghui Li Chuanmeng Niu Jianrong Dai Source Type: research

Current state of knowledge on immunotherapy in ECOG PS 2 patients. A systematic review
CONCLUSIONS: Immunotherapy seems to be justified in PS 2 patients with NSCLC. This method of treatment has been proven to be safe and tolerable. However, outcomes in this population remain suboptimal and the impact of immunotherapy in this cohort is less dramatic. Multiple scales evaluating many factors beyond PS scores have been suggested to help stratify the PS 2 to reinforce the chance of achieving better treatment outcomes. Randomized trials are needed to determine the benefits of immune checkpoint inhibitors (ICIs) for patients with poor ECOG PS.PMID:34315013 | DOI:10.1016/j.advms.2021.07.005
Source: Advances in Medical Sciences - July 27, 2021 Category: Biomedical Science Authors: Damian Mojsak Beata Kukli ńska Łukasz Minarowski Robert Marek Mr óz Source Type: research